Bernhard R. M. Ehmer
Presidente en BIOTEST AG .
Fortuna: 87 025 $ al 30/04/2024
Cargos activos de Bernhard R. M. Ehmer
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
AFFIMED N.V. | Director/Miembro de la Junta | 21/01/2016 | - |
Independent Dir/Board Member | 21/01/2016 | - | |
ACHILLES THERAPEUTICS PLC | Director/Miembro de la Junta | 04/05/2022 | - |
Independent Dir/Board Member | 04/05/2022 | - | |
BIOTEST AG | Presidente | 05/05/2022 | - |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Director/Miembro de la Junta | 01/01/2016 | - |
Historial de carrera de Bernhard R. M. Ehmer
Antiguos cargos conocidos de Bernhard R. M. Ehmer.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Presidente | 01/09/2018 | 01/06/2020 |
BIOTEST AG | Director Ejecutivo | 01/01/2015 | 01/04/2019 |
ADMA BIOLOGICS, INC. | Director/Miembro de la Junta | 06/06/2017 | 15/02/2018 |
ImClone Systems Corp. | Presidente | 01/11/2009 | 01/10/2014 |
ImClone Systems International GmbH
ImClone Systems International GmbH BiotechnologyHealth Technology ImClone Systems International GmbH develops novel therapeutic products. The company is based in Heidelberg, Germany. | Corporate Officer/Principal | 01/01/2008 | 01/01/2012 |
░░░░░░ ░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formación de Bernhard R. M. Ehmer.
Ruprecht-Karls-Universität Heidelberg | Undergraduate Degree |
Ludwig-Maximilians-Universität München | Undergraduate Degree |
Estadísticas
Internacional
Alemania | 11 |
Estados Unidos | 4 |
Francia | 2 |
Operativa
Director/Board Member | 5 |
Chief Executive Officer | 3 |
President | 3 |
Sectorial
Health Technology | 12 |
Consumer Services | 3 |
Commercial Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 6 |
---|---|
ATON | Health Technology |
ADMA BIOLOGICS, INC. | Health Technology |
MERCK KGAA | Health Technology |
BIOTEST AG | Health Technology |
AFFIMED N.V. | Health Technology |
ACHILLES THERAPEUTICS PLC | Health Technology |
Empresas privadas | 8 |
---|---|
Neovii Biotech GmbH
Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Health Technology |
BioPheresis Technologies, Inc.
BioPheresis Technologies, Inc. Medical SpecialtiesHealth Technology BioPheresis Technologies, Inc. develops technology and medical devices for the treatment of cancer. The company was founded by M. Rigdon Lentz in 1995 and is headquartered in Atlanta, GA. | Health Technology |
ImClone Systems Corp. | Health Technology |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Commercial Services |
ImClone Systems International GmbH
ImClone Systems International GmbH BiotechnologyHealth Technology ImClone Systems International GmbH develops novel therapeutic products. The company is based in Heidelberg, Germany. | Health Technology |
Biopheresis GmbH
Biopheresis GmbH Miscellaneous Commercial ServicesCommercial Services Part of BioPheresis Technologies, Inc., Biopheresis GmbH is a German company that provides cancer treatments. The private company is based in Heidelberg, Germany. | Commercial Services |
Boehringer Mannheim GmbH |
- Bolsa de valores
- Insiders
- Bernhard R. M. Ehmer
- Experiencia